checkAd

     443  0 Kommentare Valneva Commences Manufacturing of its Inactivated, Adjuvanted COVID-19 Vaccine, Completes Phase 1/2 Study Recruitment - Seite 3

    Investor and Media Contacts
    Laetitia Bachelot-Fontaine
    Director Investor Relations & Corporate Communications
    M +33 (0)6 4516 7099
    investors@valneva.com        
     

    Teresa Pinzolits
    Corporate Communications Specialist
    T +43 (0)1 20620 1116
    communications@valneva.com

    Forward-Looking Statements
    This press release contains certain forward-looking statements relating to the business of Valneva, including with respect to the progress, timing, design, data read-outs, anticipated results and completion of clinical trials for VLA2001. In addition, even if the actual results or development of Valneva are consistent with the forward-looking statements contained in this press release, those results or developments of Valneva may not be indicative of future results. In some cases, you can identify forward-looking statements by words such as "could," "should," "may," "expects," "anticipates," "believes," "intends," "estimates," "aims," "targets," or similar words. These forward-looking statements are based on the current expectations of Valneva as of the date of this press release and are subject to a number of known and unknown risks and uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievement expressed or implied by these forward-looking statements. In particular, the expectations of Valneva could be affected by, among other things, uncertainties involved in the development and manufacture of vaccines, unexpected clinical trial results, unexpected regulatory actions or delays, competition in general, currency fluctuations, the impact of the global and European credit crisis, the ability to obtain or maintain patent or other proprietary intellectual property protection and the impact of the COVID-19 pandemic. In light of these risks and uncertainties, there can be no assurance that the forward-looking statements made during this presentation will in fact be realized. Valneva is providing the information in this press release as of the date hereof and disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

    Seite 3 von 4



    Diskutieren Sie über die enthaltenen Werte



    globenewswire
    0 Follower
    Autor folgen

    Verfasst von globenewswire
    Valneva Commences Manufacturing of its Inactivated, Adjuvanted COVID-19 Vaccine, Completes Phase 1/2 Study Recruitment - Seite 3 Vaccine production initiated to optimize timeline for potential deliveries Phase 1/2 clinical study now fully enrolled; initial data read out expected in April 2021 Saint-Herblain (France), January 28, 2021 – Valneva SE, a specialty vaccine company …